Anandamide transport

被引:84
作者
McFarland, MJ [1 ]
Barker, EL [1 ]
机构
[1] Purdue Univ, Dept Med Biochem & Mol Pharmacol, W Lafayette, IN 47907 USA
关键词
cannabinoid; anandamide; transporter; Delta(9)-tetrahydorcannabinol; marijuana; amidohydrolyase;
D O I
10.1016/j.pharmthera.2004.07.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
N-Arachidonylethanolamine (anandamide) is an endogenous agonist of the cannabinoid CB1 and CB2 receptors and displays many of the same receptor-mediated physiological effects as Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active component of marijuana. As with any neurotransmitter, there must be tight control of anandamide receptor-mediated signaling and a means of rapid removal of the molecule from the system. Thus, the process by which anandamide is transported into the cell for metabolism has been a topic of much interest and has been implicated as a potential drug target in the treatment of several disease states that are reported to have an association with the endocannabinoid system. In this review, we will discuss the current models proposed for the mechanism of anandamide transport, the progress that has been made in the development of compounds that specifically inhibit anandamide transport, the observed effects of anandamide transport inhibition in vivo, and finally, potential therapeutic applications of compounds that inhibit anandamide transport. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:117 / 135
页数:19
相关论文
共 155 条
[1]   Tyrosine phosphorylation of caveolin-1 in the endothelium [J].
Aoki, T ;
Nomura, R ;
Fujimoto, T .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (02) :629-636
[2]   Endocannabinoids control spasticity in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Makriyannis, A ;
Khanolkar, A ;
Layward, L ;
Fezza, F ;
Bisogno, T ;
Di Marzo, V .
FASEB JOURNAL, 2001, 15 (02) :300-302
[3]   Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Huffman, JW ;
Layward, L .
NATURE, 2000, 404 (6773) :84-87
[4]   Functional role of high-affinity anandamide transport, as revealed by selective inhibition [J].
Beltramo, M ;
Stella, N ;
Calignano, A ;
Lin, SY ;
Makriyannis, A ;
Piomelli, D .
SCIENCE, 1997, 277 (5329) :1094-1097
[5]   Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor [J].
Beltramo, M ;
de Fonseca, FR ;
Navarro, M ;
Calignano, A ;
Gorriti, MA ;
Grammatikopoulos, G ;
Sadile, AG ;
Giuffrida, A ;
Piomelli, D .
JOURNAL OF NEUROSCIENCE, 2000, 20 (09) :3401-3407
[6]   Anandamide transport inhibition by the varmilloid agonist olvanil [J].
Beltramo, M ;
Piomelli, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 364 (01) :75-78
[7]   Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol [J].
Berrendero, F ;
Maldonado, R .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :111-117
[8]   Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes [J].
Bisogno, T ;
Maurelli, S ;
Melck, D ;
DePetrocellis, L ;
DiMarzo, V .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) :3315-3323
[9]   Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling [J].
Bracey, MH ;
Hanson, MA ;
Masuda, KR ;
Stevens, RC ;
Cravatt, BF .
SCIENCE, 2002, 298 (5599) :1793-1796
[10]   Evidence for a new G protein-coupled cannabinoid receptor in mouse brain [J].
Breivogel, CS ;
Griffin, G ;
Di Marzo, V ;
Martin, BR .
MOLECULAR PHARMACOLOGY, 2001, 60 (01) :155-163